Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in the Treatment of Keloids
NCT05128383Phase 2Completed
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Jan 2023
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dupilumab in keloid, sponsored by Beth Israel Deaconess Medical Center. Primary endpoint: Patient and Observer Scar Assessment Scale at 24 weeks. Started Jan 2023; status: completed.
02
Drugs
03
Conditions
keloid
Beyond the preview
Go deeper on NCT05128383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05128383.